Lantheus Q4 revenue $391M (+10.5%); GAAP EPS $(0.17), adj. EPS $1.59; FY25 guide $1.55B-$1.61B

Lantheus Holdings, Inc.

2024-FY EPS reported $4.36 revenue$1,533,910,000

Q4 revenue $391.1M (+10.5% YoY); PYLARIFY $266M (+15.7%), DEFINITY $86.2M (+17.9%).
GAAP fully diluted EPS $(0.17) vs $1.47 prior; adj. EPS $1.59 (-9% YoY).
Agreements to acquire Life Molecular (Alzheimer's radiodiagnostic) and Evergreen Theragnostics (manufacturing), expected H2 2025.
CMS final 2025 OPPS rule grants separate payment for PYLARIFY and other diagnostic radiopharmaceuticals.
FY 2025 revenue guidance $1.545B-$1.610B; adjusted EPS guidance $7.00-$7.20.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.